Literature DB >> 35837185

Prognostic role of myeloid-derived tumor-associated macrophages at the tumor invasive margin in gastric cancer with liver metastasis (GCLM): a single-center retrospective study.

Zeyu Wang1, Zhongyi Dong1, Gang Zhao1, Bo Ni1, Zi-Zhen Zhang1.   

Abstract

Background: Liver metastasis is one of the important factors leading to poor prognosis of gastric cancer. According to the classic "seed soil theory", it is speculated that the liver microenvironment at the invasion margin of gastric cancer liver metastases (GCLM) may have a crucial impact on tumor progression. However, few studies had stated the correlation between the patients' prognosis and the densities of stromal cells infiltrating into the invasive margin, where our retrospective study designed to identify the role of infiltrating macrophages on the prognosis of GCLM as a reliable supplement of predictive tumor markers.
Methods: The material consisted of a group of 72 gastric cancer (GC) patients with liver metastasis diagnosed from February 2015 and December 2020. The CD68+, CD206+, and Clec4f+ macrophages in their specimens were counted by immunohistochemistry (IHC), and the analysis area was the invasive margin of metastatic lesions. Clinical data were collected retrospectively. Overall survival (OS) was calculated from the date of initial diagnosis to the date of last follow-up or death. Survival analyses were performed using the Kaplan-Meier method and log-rank test. Multivariate Cox regression was performed to asses impact of macrophages on OS.
Results: The expression of CD206 could indicate the prognosis of patients with GCLM, and patients with high expression of CD206 had worse prognoses (P=0.0002). Univariate and multivariate analyses showed that CD206 was an independent risk factor for prognosis (HR 5.276, 95% CI: 1.730-16.089, P=0.003). Conclusions: The CD206+ myeloid-derived tumor associated macrophages (TAMs) may predict whether patients could benefit from R1 resection of liver-metastatic lesions, which has important theoretical significance and practical value for accurately evaluating the clinical prognosis of patients with GCLM and guiding clinical treatment. 2022 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Gastric cancer with liver metastasis (GCLM); invasion margin; prognosis; tumor-associated macrophages (TAMs)

Year:  2022        PMID: 35837185      PMCID: PMC9274044          DOI: 10.21037/jgo-22-530

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  29 in total

Review 1.  Macrophage Phenotype and Function in Different Stages of Atherosclerosis.

Authors:  Ira Tabas; Karin E Bornfeldt
Journal:  Circ Res       Date:  2016-02-19       Impact factor: 17.367

2.  Surgical treatment of liver metastases of gastric cancer: is local treatment in a systemic disease worthwhile?

Authors:  Mattia Garancini; Fabio Uggeri; Luca Degrate; Luca Nespoli; Luca Gianotti; Angelo Nespoli; Franco Uggeri; Fabrizio Romano
Journal:  HPB (Oxford)       Date:  2012-03       Impact factor: 3.647

3.  Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation.

Authors:  Ali Guner; Taeil Son; In Cho; In Gyu Kwon; Ji Yeong An; Hyoung-Il Kim; Jae-Ho Cheong; Sung Hoon Noh; Woo Jin Hyung
Journal:  Gastric Cancer       Date:  2015-08-01       Impact factor: 7.370

4.  Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302).

Authors:  Eiji Oki; Shoji Tokunaga; Yasunori Emi; Tetsuya Kusumoto; Manabu Yamamoto; Kengo Fukuzawa; Ikuo Takahashi; Sumiya Ishigami; Akihito Tsuji; Hidefumi Higashi; Toshihiko Nakamura; Hiroshi Saeki; Ken Shirabe; Yoshihiro Kakeji; Kenji Sakai; Hideo Baba; Tadashi Nishimaki; Shoji Natsugoe; Yoshihiko Maehara
Journal:  Gastric Cancer       Date:  2015-08-11       Impact factor: 7.370

5.  Hepatic resection for synchronous hepatic metastasis from gastric cancer.

Authors:  J-L Qiu; M-G Deng; W Li; R-H Zou; B-K Li; Y Zheng; X-M Lao; K Zhou; Y-F Yuan
Journal:  Eur J Surg Oncol       Date:  2013-04-08       Impact factor: 4.424

6.  Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy.

Authors:  Alfonso Tan-Garcia; Fritz Lai; Joe Poh Sheng Yeong; Sergio E Irac; Pei Y Ng; Rasha Msallam; Jeffrey Chun Tatt Lim; Lu-En Wai; Christine Y L Tham; Su P Choo; Tony Lim; Dan Y Young; Roberta D'Ambrosio; Elisabetta Degasperi; Riccardo Perbellini; Evan Newell; Nina Le Bert; Florent Ginhoux; Antonio Bertoletti; Qingfeng Chen; Charles-Antoine Dutertre
Journal:  JHEP Rep       Date:  2019-12-06

Review 7.  The changing face of gastric cancer: epidemiologic trends and advances in novel therapies.

Authors:  Raghav Chandra; Neeraja Balachandar; Sam Wang; Scott Reznik; Herbert Zeh; Matthew Porembka
Journal:  Cancer Gene Ther       Date:  2020-10-02       Impact factor: 5.987

8.  Japanese gastric cancer treatment guidelines 2018 (5th edition).

Authors: 
Journal:  Gastric Cancer       Date:  2020-02-14       Impact factor: 7.370

Review 9.  Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment.

Authors:  Kaiyue Wu; Kangjia Lin; Xiaoyan Li; Xiangliang Yuan; Peiqing Xu; Peihua Ni; Dakang Xu
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

View more
  1 in total

Review 1.  Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer.

Authors:  Chie Kudo-Saito; Narikazu Boku; Hidekazu Hirano; Hirokazu Shoji
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.